Renal Pharmacotherapy

Dosage Adjustment of Medications Eliminated by the Kidneys
2. Auflage 2021
ISBN: 978-3-030-58649-2
Verlag: Springer International Publishing

Buch, Englisch, 827 Seiten, Paperback, Format (B × H): 210 mm x 279 mm, Gewicht: 2292 g

To promote effectiveness and minimize possible toxicity, the dosage of certain medications must be adjusted in persons with compromised kidney function. Failure to enjoin appropriate dosage adjustments in patients with abnormal or rapidly changing kidney function continues to lead to reports of drug toxicity involving a broad array of renally eliminated medications.
This updated edition captures nearly 200 new drugs that have been approved by the FDA since the initial publication of Renal Pharmacotherapy. It also covers new evidence that has emerged regarding the need to adjust dosage of certain older medications that are eliminated by the kidneys. Additionally, it presents new data that are being continuously derived in the areas of patient-specific dose individualization for drugs of all types.
Comprehensive, convenient, and evidence-based, this reference closes several identified knowledge gaps and will continue to be the leading collection of dosage recommendations for patients with compromised kidney function.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Golightly, Larry K.

Teitelbaum, Isaac

Stolpman, Nancy M.

Simendinger, Bonita A.

Kiser, Tyree H.

Barber, Gerard R.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Nephrologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Pharmazie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakotherapie, Psychopharmakotherapie

Inhaltsverzeichnis

A: Acamprosate to Aztreonam.- B: Bacitracin to Butorphanol.-: Capecitabine to Cycloserine.- D: Dabigatran to Dyphylline.- E: Edetate Calcium Disodium to Exenatide.- F: Famciclovir to Fosfomycin.- H: Hetastarch to Hydroxyurea.- I: Ibandronate to Itraconazole.- K: Kanamycin to Ketorolac.- L: Lacosamide to Lurasidone.- M: Magnesium Citrate to Mycophenolate Mofetil.- N: Nabumetone to Norfloxacin.- O: Ofloxacin to Oxcarbazepine.- P: Paliperidone to Pyridostigmine.- Q: Quinapril to Quinine.- R: Ramipril to Ruxolitinib.- S: Salsalate to Sunitinib.- T: Tadalafil to Trospium.- V: Valacyclovir to Voriconazole.- Z: Zalcitabine to Zonisamide.- Proprietary Name Index.

Über Autor(innen)

Larry K. Golightly, PharmD

Clinical Research Pharmacist

University of Colorado Hospital

Aurora, CO 80045

[e-mail]



Isaac Teitelbaum, MD, FACP

Professor of Medicine

Renal Medicine and Hypertension Section, Division of General Internal Medicine

University of Colorado School of Medicine and

Director, Home Dialysis Program

University of Colorado Hospital

Aurora, CO 80045

[e-mail]



Bonita A. Simendinger, PharmD, BCPS

P&T Formulary Compliance Specialist

University of Colorado Hospital

Aurora, CO 80045

[e-mail]



Tyree H. Kiser, PharmD, BCPS, FCCP, FCCM

Professor, Department of Clinical Pharmacy

University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and

Critical Care Pharmacy Specialist

University of Colorado Hospital

Aurora, CO 80045

[e-mail]



Gerard R. Barber, RPh, MPH, FASHP

Clinical Assistant Professor, Department of Clinical Pharmacy

University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences

Aurora, CO 80045

[e-mail]



Nancy M. Stolpman, PharmD, PhD

Associate Clinical Professor

University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and

Lead Director of Pharmacy

UCHealth

Aurora, CO 80045

[e-mail]